A team of researchers has found new insight into why some lung cancer patients do not benefit from tumor-infiltrating lymphocyte, or TIL therapy. Their findings may help improve future ways to deliver ...

In this webinar, Alex George will discuss how he used high-dimensional single-cell profiling to analyze immune memory to ...

A new study reveals the C-reactive protein-albumin-lymphocyte (CALLY) index is a strong predictor of long-term survival in ...

Aptamer-based T Lymphocyte Activity Screening and SEQuencing (ATLAS-seq), to better identify antigen-reactive T cells that are more likely to offer greater immune responses against cancer cells.

Targeting clonal antigens and circumventing dysfunctional states may be important for conferring clinical responses to TIL therapy.

Here we review the B-1 subset of lymphocytes which produce self-reactive antibodies. By analyzing the IgM class of natural antibodies that recognize antigens from the nervous system, we emphasize ...

A team of researchers from Moffitt Cancer Center has found new insight into why some lung cancer patients do not benefit from tumor-infiltrating lymphocyte, or TIL therapy. Their findings, published ...